Back to List View Graph View

Cannabidiol

Cannabidiol (CBD) is a naturally occurring, non-intoxicating phytocannabinoid — a small-molecule chemical compound isolated from Cannabis sativa.

Where the papers sit

18 papers from the last 6 months study cannabidiol directly · updated from PubMed 15 Nov 2026

Study type 0 clinical trials · 2 observational · 1 human data · 14 preclinical · 1 unclassified

Themes 4 themes · 1 new direction

  • Oral Cannabidiol Delivery

    Poor aqueous solubility and limited oral exposure are driving phospholipid complexes, SNEDDS, amorphous PVP–phosphatidylcholine dispersions and poloxamer-coated exosomes. Microfluidic formulation and mechanistic modeling are being used to tune particle size, dissolution and uptake. Fixed-dose co-delivery and nanoparticle approaches extend this work toward combination and tissue-targeted therapy. In vivo pharmacokinetics remain the main test of whether these formulation gains translate.

    5 papers · 27.8%

  • Neuroinflammation and Tissue Protection

    CBD is being evaluated as a regulator of neuroinflammation, cognition and tissue resilience across neurological, metabolic and cardiac injury models. Recurring endpoints include IL-6, object recognition, blood-brain barrier integrity, endocannabinoid signaling and nerve regeneration. Effects differ by comparator and disease context, with CBG and full-spectrum oils highlighting formulation and cannabinoid-specific differences. The work is moving toward mechanism-based explanations of behavioral and cardioprotective effects, but clinical relevance remains unresolved.

    5 papers · 27.8%

  • Lennox-Gastaut Seizure Control

    Cannabidiol treatment is moving from short-term seizure reduction toward long-term, real-world assessment in Lennox-Gastaut syndrome. Drop-seizure responses are being tracked over months in adults and across genetic subgroups. The recurring endpoint is sustained reduction in seizure burden rather than symptom change alone. How genotype, treatment duration and clinical context shape response remains the key open question.

    2 papers · 11.1%

  • Others — Cannabis Therapeutic and Toxicity Studies

    CBD-rich extracts and cannabis preparations are being tested across analgesia, perioperative sedation, epilepsy, glioblastoma, head-and-neck cancer and mosquito control. Reported endpoints range from cold hyperalgesia and seizure progression to apoptosis, autophagy and insect repellency. Animal and cellular models dominate, while extract composition and dosing vary substantially. The set offers no single therapeutic direction beyond broad exploration of cannabinoid effects.

    6 papers · 33.3%

NEW DIRECTION

Cannabidiol is investigated as a mosquito-control agent rather than as a mammalian therapeutic

The adult female Aedes aegypti mosquito study treats CBD as a candidate biopesticide and repellent, outside the disease-treatment and drug-delivery roles represented elsewhere in the set. A CBD-rich hemp leaf extract caused dose-dependent adult mosquito mortality and repelled mosquitoes, whereas CBD isolate produced significantly lower mortality than the equivalent extract dose. This redirects CBD research toward vector control while also indicating that the extract’s activity cannot be attributed fully to CBD alone 42743102Sep.

cannabidiol chemical structure

Papers

The 18 papers from the last 6 months that study cannabidiol directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Oral Cannabidiol Delivery (5)
  1. Systems medicine-driven drug repurposing for respiratory infections: insights into the oral-gut-lung microbial axis and the therapeutic potential of cannabidiol and aspirin. Theory in biosciences = Theorie in den Biowissenschaften · 14 Nov 2026 PMID 43033373
  2. A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes. International journal of pharmaceutics · 25 Aug 2026 PMID 42641999
  3. Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol. Drug delivery · 23 Jul 2026 PMID 42487275
  4. Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion. AAPS PharmSciTech · 18 Jun 2026 PMID 42315741
  5. Microfluidics-Enabled Nanoparticle for Multiscale Synergetic Osteoarthritis Therapy. ACS nano · 9 Jun 2026 PMID 42261255
Neuroinflammation and Tissue Protection (5)
  1. Mechanisms by which cannabidiol promotes peripheral nerve regeneration. Neural regeneration research · 20 Oct 2026 PMID 42899815
  2. Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of molecular medicine (Berlin, Germany) · 18 Sept 2026 PMID 42758182
  3. Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease. Metabolic brain disease · 3 Sept 2026 PMID 42690466
  4. Differential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood-Brain Barrier Integrity in a Rat Model of Iron Overload. Neurotoxicity research · 28 Aug 2026 PMID 42663810
  5. Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. PloS one · 20 Jul 2026 PMID 42475352
Lennox-Gastaut Seizure Control (2)
  1. Long-Term Drop-Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox-Gastaut Syndrome. CNS neuroscience & therapeutics · 2 Nov 2026 PMID 42968542
  2. Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience. European journal of neurology · 26 Sept 2026 PMID 42798297
Others — Cannabis Therapeutic and Toxicity Studies (6)
  1. Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma. Medical oncology (Northwood, London, England) · 26 Oct 2026 PMID 42932045
  2. Toxic and repellent effects of hemp leaf extracts and cannabidiol against adult female yellow fever mosquitoes, Aedes aegypti. PloS one · 15 Sept 2026 PMID 42743102
  3. Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
  4. Cannabidiol attenuates seizure progression and recognition memory deficit induced by hippocampal HCN1 knockdown in the kindling model of epilepsy in male rats. Neuropharmacology · 30 Jul 2026 PMID 42532179
  5. Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy. Veterinary research communications · 25 Jun 2026 PMID 42348039
  6. Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. European journal of pain (London, England) · 5 Jun 2026 PMID 42248695

By study type

Observational studies and case reports (2)
  1. Long-Term Drop-Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox-Gastaut Syndrome. CNS neuroscience & therapeutics · 2 Nov 2026 PMID 42968542
  2. Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience. European journal of neurology · 26 Sept 2026 PMID 42798297
Human data, design not indexed (1)
  1. Systems medicine-driven drug repurposing for respiratory infections: insights into the oral-gut-lung microbial axis and the therapeutic potential of cannabidiol and aspirin. Theory in biosciences = Theorie in den Biowissenschaften · 14 Nov 2026 PMID 43033373
Preclinical: animal, cell and lab studies (14)
  1. Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma. Medical oncology (Northwood, London, England) · 26 Oct 2026 PMID 42932045
  2. Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of molecular medicine (Berlin, Germany) · 18 Sept 2026 PMID 42758182
  3. Toxic and repellent effects of hemp leaf extracts and cannabidiol against adult female yellow fever mosquitoes, Aedes aegypti. PloS one · 15 Sept 2026 PMID 42743102
  4. Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease. Metabolic brain disease · 3 Sept 2026 PMID 42690466
  5. Differential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood-Brain Barrier Integrity in a Rat Model of Iron Overload. Neurotoxicity research · 28 Aug 2026 PMID 42663810
  6. A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes. International journal of pharmaceutics · 25 Aug 2026 PMID 42641999
  7. Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
  8. Cannabidiol attenuates seizure progression and recognition memory deficit induced by hippocampal HCN1 knockdown in the kindling model of epilepsy in male rats. Neuropharmacology · 30 Jul 2026 PMID 42532179
  9. Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol. Drug delivery · 23 Jul 2026 PMID 42487275
  10. Chronic CBD treatment differentially modulates neurobehavioral outcomes and endocannabinoid signaling in an aged HIV-1 Tat transgenic mouse model. PloS one · 20 Jul 2026 PMID 42475352
  11. Sedative and anesthetic-sparing effects of perioperative full-spectrum cannabis oil in female dogs undergoing unilateral mastectomy and ovariohysterectomy. Veterinary research communications · 25 Jun 2026 PMID 42348039
  12. Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion. AAPS PharmSciTech · 18 Jun 2026 PMID 42315741
  13. Microfluidics-Enabled Nanoparticle for Multiscale Synergetic Osteoarthritis Therapy. ACS nano · 9 Jun 2026 PMID 42261255
  14. Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. European journal of pain (London, England) · 5 Jun 2026 PMID 42248695
Unclassified: not yet indexed with MeSH (1)
  1. Mechanisms by which cannabidiol promotes peripheral nerve regeneration. Neural regeneration research · 20 Oct 2026 PMID 42899815